Tag

Drug Pricing

All articles tagged with #drug pricing

health-policy2 days ago•11 min saved

Most states pass on Trump’s discounted GLP-1 deal, tightening Medicaid access

Trump’s plan to negotiate discounted GLP-1 weight‑loss drugs for Medicaid has stalled: only Indiana has signed on, while 29 states will not participate due to tight budgets. Twelve states still cover GLP-1s, but five of those recently ended coverage (California, Massachusetts, New Hampshire, Pennsylvania and South Carolina), with Rhode Island set to end in October. As other states weigh participation, many cite cost concerns and the risk to budget sustainability, meaning access to these drugs for low-income Americans on Medicaid is shrinking even as some argue these medications could reduce long-term health costs.

via Politico|

#drug-pricing #glp-1 #health-policy

business7 days ago•3 min saved

Hims & Hers CEO Defends FTC Case, Promises Cheaper GLP-1s and In-House AI

Hims & Hers CEO Andrew Dudum defends the company against an FTC lawsuit over data sharing and subscription practices, arguing the digital model increases access. He notes past price reductions from selling compounded GLP-1s, says Novo Nordisk dropped a patent suit and the firm now sells Novo’s branded drugs, and signals a move toward in-house AI to lower costs and transform healthcare.

via CNBC|

#ai-in-healthcare #business #drug-pricing

health24 days ago•6 min saved

Gilead's HIV PrEP Pricing Sparks Latin American Access Fight

Lenacapavir, a twice-yearly PrEP drug from Gilead that nearly prevents HIV infection, is priced at about $14,000 per dose in the US, while a reduced generic license aims for roughly $40 per dose in 120 low- and middle-income countries. Upper-middle-income Latin American countries like Brazil, Mexico, Argentina, and Peru don’t qualify, prompting protests and stalled negotiations over access. Officials and UNAIDS urge faster, broader access, as Gilead says it’s continuing regional talks and exploring other long-acting PrEP options to widen supply amid ongoing manufacturing constraints.

via Business Insider|

#access-to-medicines #drug-pricing #health

health1 month ago•50 min saved

Two Decades of GLP-1s: Obesity, Economy, and Culture in the Ozempic Era

A BuzzFeed News piece gathers Reddit discussions and user anecdotes to explore how GLP-1 medications (like Ozempic, Wegovy, and Mounjaro) could reshape society over 20 years. Predictions span obesity becoming a “disease of poverty,” shifts in beauty standards toward muscle or other traits, and the role of patent expirations and pricing in global access. The article also highlights potential economic and geopolitical effects, factory shifts in the food and insurance industries, and debates over long‑term health impacts and craving dynamics, all illustrating a future where widespread GLP-1 use could alter health, wealth, and culture.

via BuzzFeed|

#drug-pricing #glp-1-drugs #health

politics1 month ago•19 min saved

Trump drug-price rule targets 340B markups, forecasting $1.1B in Medicare savings

AP live updates report the Trump administration proposing a rule to bar hospitals from charging markups on discounted drugs for Medicare patients under the 340B program, potentially saving $1.1 billion next year; the feed also covers former CIA Director John Brennan's lawsuit to preserve records, Trump's maiden flight on a retrofitted Air Force One, his visit to the Theodore Roosevelt Presidential Library, and plans for Trump's Accounts that would give newborns $1,000.

via AP News|

#340b #brennan #drug-pricing

healthcare3 months ago•3 min saved

TrumpRx.gov Expansion Opens Transparent, Discounted Generics for Americans

President Trump announced an expansion of TrumpRx.gov to list more than 600 generic medications with transparent cash prices, enabling patients to compare the best cash prices at local pharmacies or delivery options against insurance co-pays, and integrating discounts from Amazon Pharmacy, Cost Plus Drugs, and GoodRx; the platform excludes controlled substances and meds not commonly offered direct-to-consumer, building on prior executive actions to lower US drug costs.

via The White House (.gov)|

#drug-pricing #generic-meds #healthcare

politics4 months ago•4 min saved

Trump unveils Regeneron pact to lower Medicaid drug costs

President Trump announced a deal with Regeneron to reduce prices on all Regeneron drugs sold on Medicaid, including Praluent at $225 on the TrumpRx site, as part of a broader White House drug-pricing push. Regeneron also pledged about $27 billion in U.S. R&D/manufacturing investments. Details of the contracts remain largely undisclosed, but the administration is promoting the agreements ahead of the midterm elections as part of its effort to reshape U.S. drug pricing.

via PBS|

#drug-pricing #medicaid #politics

business4 months ago•2 min saved

Regeneron trims prices for some Americans and pledges free hearing-loss gene therapy after FDA nod

Regeneron said it will lower U.S. drug prices for some Americans under President Trump’s pricing plan and will offer its first hearing-loss gene therapy for free to eligible patients after regulatory approval, while also securing a three-year tariff exemption; the therapy Otarmeni targets a rare hearing-loss condition and could reduce reliance on cochlear implants, with analysts signaling potential peak sales around $130 million.

via CNBC|

#business #drug-pricing #gene-therapy

politics4 months ago•38 min saved

Capitol Hill in Overdrive: Fed Oversight, Redistricting, and Immigration Dominate the Week

Capitol Hill is in overdrive as lawmakers tackle a torrent of issues: Senate Republicans push for increased Federal Reserve oversight to help clear the stalled Warsh nomination, while a GOP-leaning standoff over a DOJ probe adds friction. Across the Hill, Rep. Kean Jr.’s health-related absence raises concerns in New Jersey, a marathon “vote-a-rama” on immigration-enforcement funding looms in the Senate, and debate over Iran war powers intensifies as a 60-day clock nears. The Senate also moves to expand AI tools for staff, questions Kennedy’s vaccine policy, and Sanders pushes a drug-pricing amendment. In the House, FISA extension talks continue as the Endangered Species Act bill is pulled, and Virginia Democrats celebrate a redistricting win that has Hakeem Jeffries declaring “maximum warfare” in response. Polls show historic disapproval of Congress amid these fights, alongside ongoing discussions about data privacy and other Republican pregnancies on the Hill.

via Politico|

#congressional-oversight #drug-pricing #federal-reserve

politics4 months ago•31 min saved

House GOP weighs narrow immigration bill against broader reform amid FISA and redistricting drama

Live Capitol Hill updates show House Republicans weighing a quick, party-line reconciliation bill funding immigration enforcement, with support hinging on prospects for a broader package later in the year; leadership struggles over extending 702 FISA and potential long-term protections; the Endangered Species Act bill is pulled amid GOP opposition; discussions about a possible DOJ pardon for Ghislaine Maxwell surface in the Epstein case; Sanders moves to codify Trump's drug-price deals in the budget vote-a-rama; Virginia's mid-decade redistricting sparks intra-party tension as Democrats celebrate map changes; and Congress grapples with historically low public approval while Democrats prepare a marathon of affordability-focused amendments.

via Politico|

#drug-pricing #fisa #maxwell-pardon

politics4 months ago•3 min saved

Kennedy’s Capitol Hill comeback faces diminished clout amid vaccine-policy scrutiny

Health Secretary Robert F. Kennedy Jr. returns to Capitol Hill with diminished autonomy, facing a gauntlet of vaccine-related questions from House Ways and Means, Appropriations, and Senate committees as his administration’s changes—and court setbacks—have undercut his influence; critics cite the January overhaul of the childhood vaccine schedule and CDC updates tied to his stance, while supporters point to drug-pricing deals and new dietary guidelines as he maneuvers a shifting political landscape ahead of the midterms.

via Axios|

#congress #drug-pricing #politics

business4 months ago•39 min saved

Keytruda's fortress: Merck's patent-and-pricing empire under global scrutiny

An ICIJ investigation shows Merck’s Keytruda has become one of the world’s best-selling drugs not just because of therapeutic value but due to an expansive patent portfolio (more than 1,200 filings in 53 countries), lobbying, and pricing tactics that raise costs for patients worldwide while governments and insurers struggle to fund access; the report details price disparities, secrecy, accelerated approvals, and strategic moves like drug-dosing and product hopping that help Merck extend monopoly into the 2030s, with patients in India, Guatemala, the U.S. and elsewhere paying vast out-of-pocket or facing restricted access.

via International Consortium of Investigative Journalists - ICIJ|

#access-to-medicine #business #drug-pricing

politics4 months ago•8 min saved

PhRMA's Steve Ubl to step down by year-end, triggering CEO search

Steve Ubl, CEO of the Pharmaceutical Research and Manufacturers of America, will depart at the end of the year after a decade leading the branded-drug lobby, leaving a leadership gap as Congress pressures lower drug costs and the administration pursues pricing reforms. The board will search for a successor, with Ubl remaining through a smooth transition; Lori Reilly is considered a leading internal candidate as PhRMA navigates IRA-era price negotiations and rising industry scrutiny.

via Politico|

#drug-pricing #lobbying #lori-reilly

health4 months ago•19 min saved

PhRMA chief resigns amid Trump drug-pricing clash

Steve Ubl, PhRMA’s CEO, will step down after steering the drug industry toward a tougher lobbying stance as Washington and President Trump spar over drug prices, including threats of tariffs; a successor will be named as the pricing fight continues.

via The Washington Post|

#donald-trump #drug-pricing #health

health5 months ago•5 min saved

TrumpRx: Small Discounts, Big Questions on Real Price Relief

TrumpRx.gov, launched to curb prescription costs, has offered discounts on only 54 drugs—many with cheaper generics or other savings options—and remains far from an insurance-friendly tool, with limited awareness; experts say its real impact hinges on scale, broader drug coverage, price transparency, and potential congressional action to codify MFN-style deals into law.

via NBC News|

#drug-pricing #health #health-policy